

May 14, 2020



To NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUOPHARMA	To BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub: Disclosure under Reg. 30 of SEBI (LODR) Regulations 2015 - Settlement Order dated May 06, 2020 passed by the Securities and Exchange Board of India ("SEBI").

Ref: Our Letter dated September 24, 2019.

As previously disclosed, SEBI had passed an Adjudication Order dated September 23, 2019 ("**AO Order**") against the Company and Mr. P.V. Ramprasad Reddy, Mrs. P. Suneela Rani, Mr. Kambam Prasad Reddy, Veritaz Healthcare Limited and Trident Chemphar Limited, promoters of the Company. On October 24, 2019, the AO Order was challenged before the Securities Appellate Tribunal in Appeal (L) No. 543 of 2019 ("**SAT Appeal**").

During the pendency of the appeal, on October 25, 2019, the Company filed a settlement application before SEBI under the SEBI (Settlement Proceedings) Regulations, 2018 ("**Settlement Regulations**") in respect of the SAT Appeal. On October 25, 2019, the promoters of the Company also filed a settlement application before SEBI under the Settlement Regulations in respect of the SAT Appeal and, in accordance with Regulation 3(4) of the Settlement Regulations, in respect of Show Cause Notice dated September 06, 2017 ("**11B SCN**") issued to the promoters of the Company under Section 11(1), 11(4) and 11B of the SEBI Act, 1992.

The Company has been informed by SEBI today that SEBI has passed a settlement order dated May 06, 2020 bearing ref. no. SO/EFD-2/SD/346/MAY/2020 ("**Settlement Order**") in respect of the abovementioned settlement applications filed by the Company and its promoters. The settlement applications pertained to alleged violation of SEBI (Prohibition of Insider Trading) Regulations, 1992 and were based on an undertaking by the Company and its promoters without admitting or denying the findings of fact and conclusions of law. The Company has paid a settlement amount of Rs.2,20,00,000/- (Rupees Two Crore Twenty Lakh only) and Rs. 60,000/- (Rupees Sixty Thousand) as legal costs. The promoters have cumulatively paid a settlement amount of Rs. 19,81,65,000/- (Rupees Nineteen Crore Eighty One Lakh and Sixty Five Thousand only) and Rs. 60,000/- (Rupees Sixty Thousand only) each, as legal costs. In terms of the Settlement Order, pending enforcement proceedings stand settled qua the Company and its promoters and no enforcement action will be initiated by SEBI in respect of the aforesaid allegations.

This is for your information and records.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary



AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivi, Ameerpet, Hyderabad - 500 038. T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com